On March 27, Gelonghui (03933.HK) announced its 2023 annual results announcement. During the year under review, the Group recorded a turnover of approximately RMB 13.794 billion, an increase of about 21.2% over 2022. Profit attributable to company owners was RMB 2,701 billion, an increase of 70.9% over the previous year. Earnings per share were RMB 148.67 cents. The Board recommended a final dividend of RMB 28 points per share and a special dividend of RMB 12 points per share. Together with the interim dividend of RMB 12 per share already paid, the annual dividend is RMB 52 cents per share.
GLP-1 drugs are booming, major products continue to emerge, and the expansion of many new indications has further spawned huge market potential. Focusing on the GLP-1 target, the Group has laid out a differentiated product pipeline combining innovative drugs and biosimilar drugs. During the year, the Class 1 innovative drug UBT251 injection was approved for clinical trials in China and the US. The group became the first domestic company and the second company in the world to receive clinical approval for long-acting GLP-1 (glucagon-like peptide-1) /GIP (glucose-dependent insulin-promoting polypeptide) /GCG (glucagon) triagonists prepared by chemical synthesis of polypeptides; simeglutide injections and liraglutide injections have also made positive progress. The Group focuses on the fields of metabolism, autoimmunity, ophthalmology and anti-infection, and continues to expand the pipeline of new drugs being developed. TUL12101 eye drops, a new class 1 drug to treat dry eye syndrome, and TUL01101 tablets, a new class 1 drug to treat moderate to severe atopic dermatitis, were approved for clinical trials during the year. This year, the Group's R&D investment reached RMB 808 million, an increase of 36.2% over the previous year.